CFH

Blackhawk Network (BHN) Partners with Roblox to Expand Launch of Digital Gift Cards

Retrieved on: 
Wednesday, February 14, 2024

Leading branded payments provider, Blackhawk Network (BHN), has partnered with Roblox, a global immersive platform for communication and connection, to offer Austrian (EUR), Belgian (EUR), Swiss Franc (CFH), and Brazilian Real (BRL) digital gift cards on Roblox’s gift card site, Roblox.com/giftcards .

Key Points: 
  • Leading branded payments provider, Blackhawk Network (BHN), has partnered with Roblox, a global immersive platform for communication and connection, to offer Austrian (EUR), Belgian (EUR), Swiss Franc (CFH), and Brazilian Real (BRL) digital gift cards on Roblox’s gift card site, Roblox.com/giftcards .
  • Consumers in each respective country can now purchase Roblox digital gift cards in their local currencies.
  • Roblox digital gift cards enable users to purchase Robux, the platform’s virtual currency, which is used to acquire digital items and accessories for an enhanced and more personalized experience.
  • This expansion follows the November 2023 announcement from BHN that consumers throughout Japan can now purchase digital Roblox gift cards .

HSBC UK partners with Nova Credit to become first UK bank to offer newcomers option to include international credit history when applying for a credit card

Retrieved on: 
Monday, September 18, 2023

“Opening a credit card and building credit is an important step when setting up life in a new country.

Key Points: 
  • “Opening a credit card and building credit is an important step when setting up life in a new country.
  • Access credit faster: leverage credit history built up overseas, using Nova Credit’s Nova Passport technology, to start a positive credit history in the UK on arrival.2
    3.
  • More information on HSBC UK’s international banking services: www.hsbc.co.uk/international/
    Images available: Screenshot of credit card application journey on mobile and image of an HSBC UK credit card.
  • International Credit Decisioning (ICD) has been available from March 2023 in the UK, enabling credit history transfer from 12 countries for HSBC UK credit card applications.

Jones Soda Co. Announces Appointment of David Knight as New President and Chief Executive Officer

Retrieved on: 
Thursday, June 8, 2023

Mr. Knight has a Bachelor of Business, Marketing from the University of New South Wales in Sydney, Australia.

Key Points: 
  • Mr. Knight has a Bachelor of Business, Marketing from the University of New South Wales in Sydney, Australia.
  • I believe Jones is well-positioned for continued growth and I look forward to building on the momentum that Mark has started,” stated Mr. Knight.
  • Mr. Knight will succeed Mark Murray, who while retiring as the Company‘s President and Chief Executive Officer, will continue to remain on the Board as a director.
  • “On behalf of the full Board, I would like to thank Mark for his tireless service to Jones as President and CEO.

Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H

Retrieved on: 
Monday, April 24, 2023

MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq: FDMT) (“4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large-market diseases, today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.

Key Points: 
  • MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq: FDMT) (“4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large-market diseases, today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.
  • Under the terms of the agreement, 4DMT will make cash payments to Aevitas totaling up to ~$140 million in potential late-stage development, regulatory and sales milestones.
  • A range of single-digit royalties on net sales are also payable.
  • Partnering with 4DMT further validates the Fortress business model of identifying and developing promising treatments for patients, while pursuing opportunities that potentially maximize shareholder value.

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

Retrieved on: 
Monday, April 24, 2023

Geographic atrophy is a highly prevalent disease with a significant unmet medical need.

Key Points: 
  • Geographic atrophy is a highly prevalent disease with a significant unmet medical need.
  • According to published estimates, there are over one million individuals with GA in the U.S. alone as of 2022.
  • The first treatment for GA, complement inhibitor pegcetacoplan injection, was approved in the U.S. in February 2023 and is administered by intravitreal (IVT) injection once every 25 to 60 days.
  • Complement Factor H (CFH) is a master regulator of the complement system, functioning as a natural inhibitor of the alternative complement pathway.

medZERO Adds Another FinTECH Award at Meta Lab Challenge

Retrieved on: 
Tuesday, June 7, 2022

medZERO is a national Mobile lending & healthcare payments platform that makes healthcare affordable for employees struggling to pay their bills.

Key Points: 
  • medZERO is a national Mobile lending & healthcare payments platform that makes healthcare affordable for employees struggling to pay their bills.
  • Businesses and healthcare providers headquartered throughout the Charlotte region have the opportunity to participate in the Meta Lab medZERO program with discounts and rewards available for those who sign up quickly.
  • The goals of the challenge aligned with our mission perfectly, said Craig Froude, medZERO CEO and co-founder.
  • The Meta Lab is a forward-thinking collaboration among Charlottes city leaders in fintech and healthtech to cultivate a world-leading ecosystem for innovation and collaboration.

AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board

Retrieved on: 
Wednesday, June 1, 2022

We look forward to their contributions in support of our effort to develop a treatment for dry AMD.

Key Points: 
  • We look forward to their contributions in support of our effort to develop a treatment for dry AMD.
  • Jeff Heier, a newly appointed member of the SAB, added, I feel privileged to be a part of this distinguished group of clinicians during this exciting time at AGTC.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • Its preclinical programs build on the companys industry leading AAV manufacturing technology and scientific expertise.

Gemini Therapeutics Reports 2021 Financial Results

Retrieved on: 
Thursday, March 10, 2022

Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.
  • Gemini reported a net loss of $71.9 million for the full year 2021 compared to $40.8 million for the same period in 2020.
  • Research and development expenses were $48.7 million and $28.2 million for the twelve months ended December 31, 2021 and 2020, respectively.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

Hemp Bioscience Company CFH Releases Its ProLine of Clinical-Strength CBD Wellness Products

Retrieved on: 
Thursday, March 3, 2022

Longmont, Colo., March 03, 2022 (GLOBE NEWSWIRE) -- Colorado-based hemp bioscience company CFH, Ltd. , launches a Rapid Relief Roll-on Gel and Relief Cream as a part of its ProLine.

Key Points: 
  • Longmont, Colo., March 03, 2022 (GLOBE NEWSWIRE) -- Colorado-based hemp bioscience company CFH, Ltd. , launches a Rapid Relief Roll-on Gel and Relief Cream as a part of its ProLine.
  • The CFH ProLine, which debuted as a lineup of professional-grade full-spectrum hemp extract products for clinical use, is now available online nationwide at www.CFH.Ltd .
  • The vertically integrated company controls all aspects of product development to ensure all products are made with the highest quality hemp.
  • Founded in 2014, CFH, Ltd. is Colorado-based, vertically integrated hemp bioscience company and a leading supplier of CBD nationwide.

Gemini Therapeutics Provides Corporate Update

Retrieved on: 
Monday, February 28, 2022

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.
  • As part of its corporate restructuring, Gemini intends to reduce its workforce by 24 employees, approximately 80 percent, by the end of the second quarter of 2022 with remaining employees focused on GEM307s IND-enabling tasks.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.